ESMO 2026 preview spotlights upcoming abstracts from Zai Lab, GSK and Merck
The European Society for Medical Oncology (ESMO) meeting returns to Madrid in 2026, featuring a slate of abstracts expected from several major biotech and pharmaceutical companies.
Among the anticipated presentations are data from Zai Lab, GSK and Merck, covering a range of therapeutic areas. The preview notes that previous sessions, such as a first‑line bladder cancer study, received strong audience reaction.
The article suggests that the upcoming abstracts could generate similar interest, though specific results have not yet been disclosed.
Readers are encouraged to subscribe for full access to the detailed reports and analyses.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and more”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that